FGF-2 Polyclonal Antibody
¥680.00
Cleaved-Integrin αV HC (K889) Polyclonal Antibody
活动价：
¥680.00
市场价：¥880.00
一键复制产品信息
产品规格：
- 50μL
- 100μL
货号：
FAB2600085
- 产品信息
商品描述
靶点-Target
Integrin αV
反应性
Human,Rat,Mouse,
应用
WB,ELISA
宿主物种-Host Species
Rabbit
同种型-Isotype
IgG
修饰-Modification
Unmodified
MW(Observed)
95kD
推荐稀释比
WB 1:500-1:2000;ELISA 1:10000;Not yet tested in other applications.
组成
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
纯化工艺
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
储存
-15°C to -25°C/1 year(Do not lower than -25°C)
浓度
1 mg/ml
克隆性
Polyclonal
免疫原
The antiserum was produced against synthesized peptide derived from human ITGAV. AA range:840-889
特异性
Cleaved-Integrin αV HC (K889) Polyclonal Antibody detects endogenous levels of fragment of activated Integrin αV HC protein resulting from cleavage adjacent to K889.
基因名称
ITGAV
蛋白名称
Integrin alpha-V
别名
ITGAV;MSK8;VNRA;Integrin alpha-V;Vitronectin receptor subunit alpha;CD antigen CD51
Organism-1
Human
基因ID-1
3685
SwissProt-1
P06756
Organism-2
Mouse
SwissProt-2
P43406
背景
integrin subunit alpha V(ITGAV) Homo sapiens The product of this gene belongs to the integrin alpha chain family. Integrins are heterodimeric integral membrane proteins composed of an alpha subunit and a beta subunit that function in cell surface adhesion and signaling. The encoded preproprotein is proteolytically processed to generate light and heavy chains that comprise the alpha V subunit. This subunit associates with beta 1, beta 3, beta 5, beta 6 and beta 8 subunits. The heterodimer consisting of alpha V and beta 3 subunits is also known as the vitronectin receptor. This integrin may regulate angiogenesis and cancer progression. Alternative splicing results in multiple transcript variants. Note that the integrin alpha 5 and integrin alpha V subunits are encoded by distinct genes. [provided by RefSeq, Oct 2015],
细胞定位
Cell membrane; Single-pass type I membrane protein. Cell junction, focal adhesion .
